Clinical characteristics and prognosis of Omicron epidemic in Guang’an_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

WEI Ailin ¹ , LI Yichuan ² , GU Yonglin ² , PENG Suyun ³ , YAN Min ³ , ZHANG Xuemei ⁴ ,  MA Qing ³

1. Department of Science and Education, Guang’an People’s Hospital, Guang’an, 638000, Sichuan, P. R. China;
2. Department of Medical Administration, Guang’an People’s Hospital, Guang’an, 638000, Sichuan, P. R. China;
3. Department of Operations Management, Guang’an People’s Hospital, Guang’an, 638000, Sichuan, P. R. China;
4. Department of Party Committee Office, Guang’an People’s Hospital, Guang’an, 638000, Sichuan, P. R. China;

Corresponding author：

MA Qing, Email: 1838998@qq.com

Keywords：

COVID-19; clinical characteristics; high-risk factors; shelter management

DOI：

10.7507/1007-4848.202302027

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze the clinical characteristics of the Guang’an Omicron epidemic and summarize the management experiences and practices in pandemic prevention and control of major infectious diseases.Methods Retrospective analysis was performed on patients infected with coronavirus disease (COVID-19), afterwards treated and observed in the isolation ward of Guang’an People’s Hospital and the shelter of Guang’an City from May 9 to June 26, 2022. The characteristics of patients at different age stages and the related factors affecting the severity, re-positive and negative conversion was analyzed. Results Finally 1 278 patients were collected, including 508 males and 770 females, with an average age of 41.3±22.6 years. Among them, 1 054 patients were asymptomatic carriers. The overall severe rate was 0.86%, the severe rate of the high-risk group was 3.06%. The median negative conversion time was 10.0 days and re-positive rate was 7.36%. Patients aged＞60 years were 2.589 times more likely to have a longer negative conversion time than those aged≤60 years (95%CI 1.921-3.489, P＜0.001). Conclusion The clinical characteristics of Guang’an COVID-19 epidemic are mainly that the elderly with high risk factors are more likely to develop severe cases, have longer clearance time, and re-positve is more likely to occur.

Citation： WEI Ailin, LI Yichuan, GU Yonglin, PENG Suyun, YAN Min, ZHANG Xuemei, MA Qing. Clinical characteristics and prognosis of Omicron epidemic in Guang’an. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30(7): 970-975. doi: 10.7507/1007-4848.202302027 Copy

1.	Schreiber M. The scientist in Botswana who identified omicron was saddened by the world's reaction. NPR. https://tinyurl.com/at2c6u3n. Accessed on 2022-01-25.
2.	World Health Organization Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-con. Accessed on 2021-11-26.
3.	Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ, 2021, 375: n2943.
4.	Desingu PA, Nagarajan K, Dhama K. Emergence of Omicron third lineage BA. 3 and its importance. J Med Virol, 2022, 94(5): 1808-1810.
5.	Majumdar S, Sarkar R. Mutational and phylogenetic analyses of the two lineages of the Omicron variant. J Med Virol, 2022, 94(5): 1777-1779.
6.	Qu P, Evans JP, Faraone J, et al. Distinct neutralizing antibody escape of SARS-CoV-2 Omicron subvariants BQ. 1, BQ. 1.1, BA. 4.6, BF. 7 and BA. 2.75. 2. bioRxiv, 2022, 2022.10. 19.512891.
7.	Cao Y, Yisimayi A, Jian F, et al. BA. 2. 12. 1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection. Nature, 2022, 608(7923): 593-602.
8.	Zhang X, Zhang W, Chen S. Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet, 2022, 399(10340): 2011-2012.
9.	中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版). 中华临床感染病杂志, 2022, 15(2): 81-89.
10.	Gómez-Ochoa SA, Franco OH, Rojas LZ, et al. COVID-19 in health-care workers: A living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. Am J Epidemiol, 2021, 190(1): 161-175.
11.	Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol, 2021, 93(3): 1449-1458.
12.	Chen J, Wang R, Gilby NB, et al. Omicron variant (B. 1.1. 529): Infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model, 2022, 62(2): 412-422.
13.	Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: A data linkage study. Lancet, 2022, 399(10323): 437-446.
14.	Maslo C, Friedland R, Toubkin M, et al. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA, 2022, 327(6): 583-584.
15.	UKHSA. SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 31, 2021. https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings.
16.	Torjesen I. Covid-19: Omicron variant is linked to steep rise in hospital admissions of very young children. BMJ, 2022, 376: o110.
17.	Bhattacharyya RP, Hanage WP. Challenges in inferring intrinsic severity of the SARS-CoV-2 Omicron variant. N Engl J Med, 2022, 386(7): e14.
18.	Elliott J, Bodinier B, Whitaker M, et al. COVID-19 mortality in the UK biobank cohort: Revisiting and evaluating risk factors. Eur J Epidemiol, 2021, 36(3): 299-309.
19.	Singh AK, Gillies CL, Singh R, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes Obes Metab, 2020, 22(10): 1915-1924.
20.	Singh AK, Khunti K. COVID-19 and diabetes. Annu Rev Med, 2022, 73: 129-147.
21.	Kang YJ. South Korea's COVID-19 infection status: From the perspective of re-positive test results after viral clearance evidenced by negative test results. Disaster Med Public Health Prep, 2020, 14(6): 762-764.
22.	Zou Y, Wang BR, Sun L, et al. The issue of recurrently positive patients who recovered from COVID-19 according to the current discharge criteria: Investigation of patients from multiple medical institutions in Wuhan, China. J Infect Dis, 2020, 222(11): 1784-1788.
23.	Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med, 2020, 382(12): 1177-1179.
24.	Spitzer A, Angel Y, Marudi O, et al. Association of a third dose of BNT162b2 vaccine with incidence of SARS-CoV-2 infection among health care workers in Israel. JAMA, 2022, 327(4): 341-349.
25.	Fleming-Dutra KE, Britton A, Shang N, et al. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance. JAMA, 2022, 327(22): 2210-2219.
26.	Hong Kong Centre for Health Protection of the Department of Health, and the Hospital Authority. Statistics on 5th wave of COVID-19. Sep 20, 2022. https://www.covidvaccine.gov. hk/pdf/5th_wave_statistics.pdf. Accessed on 2022-9-20.
27.	徐湘茹, 孙鼎, 曹敏, 等. 上海市4 264例无症状及轻型新冠病毒感染者临床特征及预后转归分析. 中华危重病急救医学, 2022, 34(5): 449-453.

1. Schreiber M. The scientist in Botswana who identified omicron was saddened by the world's reaction. NPR. https://tinyurl.com/at2c6u3n. Accessed on 2022-01-25.
2. World Health Organization Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-con. Accessed on 2021-11-26.
3. Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ, 2021, 375: n2943.
4. Desingu PA, Nagarajan K, Dhama K. Emergence of Omicron third lineage BA. 3 and its importance. J Med Virol, 2022, 94(5): 1808-1810.
5. Majumdar S, Sarkar R. Mutational and phylogenetic analyses of the two lineages of the Omicron variant. J Med Virol, 2022, 94(5): 1777-1779.
6. Qu P, Evans JP, Faraone J, et al. Distinct neutralizing antibody escape of SARS-CoV-2 Omicron subvariants BQ. 1, BQ. 1.1, BA. 4.6, BF. 7 and BA. 2.75. 2. bioRxiv, 2022, 2022.10. 19.512891.
7. Cao Y, Yisimayi A, Jian F, et al. BA. 2. 12. 1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection. Nature, 2022, 608(7923): 593-602.
8. Zhang X, Zhang W, Chen S. Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet, 2022, 399(10340): 2011-2012.
9. 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版). 中华临床感染病杂志, 2022, 15(2): 81-89.
10. Gómez-Ochoa SA, Franco OH, Rojas LZ, et al. COVID-19 in health-care workers: A living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. Am J Epidemiol, 2021, 190(1): 161-175.
11. Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol, 2021, 93(3): 1449-1458.
12. Chen J, Wang R, Gilby NB, et al. Omicron variant (B. 1.1. 529): Infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model, 2022, 62(2): 412-422.
13. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: A data linkage study. Lancet, 2022, 399(10323): 437-446.
14. Maslo C, Friedland R, Toubkin M, et al. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA, 2022, 327(6): 583-584.
15. UKHSA. SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 31, 2021. https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings.
16. Torjesen I. Covid-19: Omicron variant is linked to steep rise in hospital admissions of very young children. BMJ, 2022, 376: o110.
17. Bhattacharyya RP, Hanage WP. Challenges in inferring intrinsic severity of the SARS-CoV-2 Omicron variant. N Engl J Med, 2022, 386(7): e14.
18. Elliott J, Bodinier B, Whitaker M, et al. COVID-19 mortality in the UK biobank cohort: Revisiting and evaluating risk factors. Eur J Epidemiol, 2021, 36(3): 299-309.
19. Singh AK, Gillies CL, Singh R, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes Obes Metab, 2020, 22(10): 1915-1924.
20. Singh AK, Khunti K. COVID-19 and diabetes. Annu Rev Med, 2022, 73: 129-147.
21. Kang YJ. South Korea's COVID-19 infection status: From the perspective of re-positive test results after viral clearance evidenced by negative test results. Disaster Med Public Health Prep, 2020, 14(6): 762-764.
22. Zou Y, Wang BR, Sun L, et al. The issue of recurrently positive patients who recovered from COVID-19 according to the current discharge criteria: Investigation of patients from multiple medical institutions in Wuhan, China. J Infect Dis, 2020, 222(11): 1784-1788.
23. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med, 2020, 382(12): 1177-1179.
24. Spitzer A, Angel Y, Marudi O, et al. Association of a third dose of BNT162b2 vaccine with incidence of SARS-CoV-2 infection among health care workers in Israel. JAMA, 2022, 327(4): 341-349.
25. Fleming-Dutra KE, Britton A, Shang N, et al. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance. JAMA, 2022, 327(22): 2210-2219.
26. Hong Kong Centre for Health Protection of the Department of Health, and the Hospital Authority. Statistics on 5th wave of COVID-19. Sep 20, 2022. https://www.covidvaccine.gov. hk/pdf/5th_wave_statistics.pdf. Accessed on 2022-9-20.
27. 徐湘茹, 孙鼎, 曹敏, 等. 上海市4 264例无症状及轻型新冠病毒感染者临床特征及预后转归分析. 中华危重病急救医学, 2022, 34(5): 449-453.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Clinical characteristics and prognosis of Omicron epidemic in Guang’an

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content